end stage renal disease. Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: Pearl vitamin D 50000 units, manufactured by Zahravi Pharmaceutical Company. 1 perl in week. If serum vit D less than 10ng/mL for 12 weeks. If serum vit D 10-30ng/mL for 8 weeks. Inter
Treatment - Drugs
Placebo
Pearl vitamin D 50000 units, manufactured by Zahravi Pharmaceutical Company. 1 perl in week. If serum vit D less than 10ng/mL for 12 weeks. If serum vit D 10-30ng/mL for 8 weeks.
Placebo pearl, manufactured by Zahravi Pharmaceutical Company. 1 perl in week. If serum vit D less than 10ng/mL for 12 weeks. If serum vit D 10-30ng/mL for 8 weeks.
Sponsors
Vice Chancellor for Research, Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1- Minimum duration of peritoneal dialysis for 3 months. 2- No treatment with vitamin D. 3- Patient satisfaction. Exclusion criteria: 1- History of malignancy. 2- History of myocardial infarction or heart failure in 3 months ago. 3- Serum level of vitamin D more than 30ng/m. 4- Calcium-phosphorus product more than 55.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum vitamin D level. Timepoint: Baseline, at the end of the study. Method of measurement: ng/mL.;Adequacy of dialysis. Timepoint: Baseline, at the end of the study. Method of measurement: software.;Serum Pro BNP level. Timepoint: Baseline, at the end of the study. Method of measurement: pg/mL. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum calcium level. Timepoint: Baseline, at the end of the study. Method of measurement: mg/dL.;Serum Parathormon level. Timepoint: Baseline, at the end of the study. Method of measurement: pg/dL. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mojgan Mortazavi
Isfahan University of Medical Science
Outcome results
None listed